Dupilumab
- BNF:
- Not listed
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- June 2017
Comments
RED:
- NICE TA534: for treating moderate to severe atopic dermatitis. (Decision date - Sep 2018).
- Dupiliumab has been awarded an EAMS status for severe
atopic dermatitis.
- NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation. (Decision date - February 2022).
- Use in children 6 to 11 years old as add-on maintenance treatment for
severe asthma with type 2 inflammation. (NHSE commissioned.) (Decision date - October 2022).
DO NOT PRESCRIBE (DNP):
- NICE TA648: for treating chronic rhinosinusitis with nasal polyps. (Terminated appraisal). (Decision date - October 2020).
- NICE TA938: for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). (Decision date - January 2024)
- NICE TA955: for treating moderate to severe prurigo nodularis. Not recommended. (Decision date - April 2024)
Black Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again